Home/Pipeline/Tocilizumab

Tocilizumab

Rheumatoid Arthritis

FiledRegulatory Review

Key Facts

Indication

Rheumatoid Arthritis

Phase

Filed

Status

Regulatory Review

Company

Biocon

About Biocon

Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.

View full company profile

Therapeutic Areas

Diabetes Oncology Immunology Autoimmune Diseases Nephrology

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
CORTONE (cortisone)	Merck	Commercial	Active
Kevzara (sarilumab)	Regeneron Pharmaceuticals	Approved	Commercial
Actemra (tocilizumab)	Chugai Pharmaceutical	Approved	Commercial
Humira	Abbott India	Approved	Commercial
KPL-404	Kiniksa Pharmaceuticals	Phase 2	In Development
Tibulizumab (ZB-106)	Zura Bio	Phase 1b	Completed
Zunsemetinib (ATI-450)	Aclaris Therapeutics	Phase 2b	Active
Natrunix Program	XBiotech	Not Specified	Active
LEAPS Technology	CEL-SCI	Pre-clinical	Early Development
Piclidenoson (CF101)	Can Fite Biopharma	Phase 3	Active/Completed
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)